Sabon Nazarin Ƙarfafa J&J: 85% Tasiri Akan Asibitin COVID-19

A KYAUTA Kyauta 6 | eTurboNews | eTN
Avatar na Linda Hohnholz
Written by Linda Hohnholz

Wani bincike na daban ya nuna Johnson & Johnson COVID-19 mai ƙarfafa rigakafin rigakafin ya haifar da haɓaka ninki 41 a cikin kawar da ƙwayoyin rigakafi da haɓakar 5-nkunin ƙwayoyin T akan Omicron.

Johnson & Johnson a yau sun sanar da sabon sakamako na farko daga binciken Phase 3b Sisonke na Afirka ta Kudu wanda ya nuna cewa wani nau'in allurar rigakafi iri daya na maganin rigakafin Johnson & Johnson COVID-19 (Ad26.COV2.S) ya nuna tasirin kashi 85 kan COVID- 19 masu alaka da asibiti. Binciken, wanda Cibiyar Nazarin Likitoci ta Afirka ta Kudu (SAMRC) ta gudanar, ya nuna cewa haɓakar Johnson & Johnson ya rage haɗarin asibiti daga COVID-19 tsakanin ma'aikatan kiwon lafiya a Afirka ta Kudu bayan Omicron ya zama babban bambance-bambancen. A cikin watannin da aka yi nazari (tsakiyar Nuwamba zuwa tsakiyar Disamba) yawan Omicron ya karu daga kashi 82 zuwa 98 na shari'o'in COVID-19 a Afirka ta Kudu kamar yadda GISAID ya ruwaito, wani shiri da ke ba da bayanan COVID-19.     

Na biyu, bincike daban-daban game da martanin rigakafin rigakafi ga tsarin rigakafi daban-daban, wanda Cibiyar Kiwon Lafiya ta Beth Israel Deaconess (BIDMC) ta gudanar, ya nuna cewa wani nau'in haɓaka mai ƙarfi (alurar rigakafi daban-daban) na rigakafin Johnson & Johnson COVID-19 a cikin mutanen da suka fara karɓar BNT162b2 Alurar rigakafin mRNA ta haifar da karuwa mai ninki 41 a cikin kawar da martanin antibody da haɓakar ninki 5 a cikin ƙwayoyin CD8+ zuwa Omicron da makonni huɗu bayan haɓakawa. Haɓakawa mai kama da juna tare da BNT162b2 ya haifar da haɓakar ninki 17 a cikin kawar da ƙwayoyin rigakafi da haɓakar ninki 1.4 a cikin ƙwayoyin CD8+ T da makonni huɗu bayan haɓakar. Dukansu antibodies da CD8+ T-cell sun fi girma makonni hudu bayan haɓaka tare da rigakafin Johnson & Johnson fiye da na BNT162b2.

Haɓakawa a cikin ƙwayoyin CD8+ T da allurar Johnson & Johnson ke samarwa na iya zama mabuɗin don bayyana manyan matakan tasiri akan cutar COVID-19 mai tsanani da kuma asibiti a cikin binciken Sisonke 2, kamar yadda aka nuna bambance-bambancen Omicron don tserewa kawar da ƙwayoyin cuta.

An ƙaddamar da bayanan zuwa uwar garken da aka riga aka buga medRxiv ta marubutan binciken, tare da tsammanin bugawa a cikin mujallun da aka yi bita na tsara.

Mataki na 3b Sisonke 2 Karatuttukan Shot na Ƙarawa a cikin Ma'aikatan Kiwon Lafiya na Afirka ta Kudu

Bayanai daga gwajin Sisonke 2 (n=227,310), wanda aka gudanar tsakanin ma'aikatan kiwon lafiya a Afirka ta Kudu wadanda suka sami allurar rigakafin Johnson & Johnson COVID-19 a matsayin kashi na farko, sun nuna cewa Johnson & Johnson COVID-19 yana haɓaka tasirin rigakafin. (VE) a kan asibiti zuwa kashi 85. Lokacin da aka yi amfani da harbi mai ƙarfafawa watanni shida zuwa tara bayan kashi ɗaya na farko, VE ya karu akan lokaci daga 63 bisa dari (95% CI, 31-81%) a kwanakin 0-13, zuwa kashi 84 (95% CI, 67-92). %) a kwanakin 14-27 da kashi 85 (95% CI, 54-95%) a watanni 1-2 bayan haɓakawa.

An gudanar da Sisonke 2 a kusan cibiyoyin rigakafin 350 a duk larduna tara na Afirka ta Kudu. Yin amfani da bayanai daga Lafiya na Discovery, ƙungiyar kulawa da Afirka ta Kudu, masu binciken gwaji sun ƙaddara VE na Johnson & Johnson COVID-19 mai ƙarfafa harbi (n=69,092) idan aka kwatanta da sauran mutanen da suka yi rajista a cikin ƙungiyar kulawa iri ɗaya, a cikin lokacin daga Nuwamba. 15, 2021, zuwa Disamba 20, 2021.

An fara rajista don Sisonke 2 hannu na gwajin kafin farawar Omicron a Afirka ta Kudu, yana ba masu bincike damar tantance tasirin rigakafin COVID-19 na Kamfanin musamman kamar yadda Omicron ya zama babban bambance-bambance a cikin ƙasar. Ba a gudanar da keɓancewar jinsi na keɓancewa daga shari'o'in COVID-19 a cikin wannan gwajin ba.

Ma'aikatan kiwon lafiya suna da haɗarin kamuwa da cutar ta COVID-19, kuma a cikin ƙasashe irin su Afirka ta Kudu, waɗanda ke da yawan jama'a da ke fama da cututtuka, tasirin cututtukan SARS-CoV-2 a cikin ma'aikatan kiwon lafiya suna da zurfi sosai. Yawancin ma'aikatan kiwon lafiya na Afirka ta Kudu da suka mutu ta hanyar COVID-19 suna da aƙalla cuta guda ɗaya, kuma da yawa suna da cututtuka da yawa.

Martanin Antibody da T-Cell Bayan Tsarin Ƙarfafa Ƙarfafa Ƙwararru Mafi Girma fiye da Bayan Tsarin Homologous Akan Bambancin Omicron

Binciken mutane 65 da suka sami alluran rigakafi na farko tare da allurai biyu na rigakafin mRNA COVID-19 (BNT162b2), sannan kuma wani harbin haɓakar homologous na BNT162b2 (n=24) ko mai haɓaka haɓaka tare da rigakafin Johnson & Johnson COVID-19 ( n=41) bayan aƙalla watanni shida, an gano tsarin duka biyun sun haɓaka martanin ban dariya da na salula akan Omicron.

Maganin rigakafin rigakafin cutar Omicron duka biyun rigakafin Johnson & Johnson COVID-19 da rigakafin BNT162b2 ne suka haɓaka, tare da rigakafin Johnson & Johnson COVID-19 yana ƙara kawar da titers antibody da ninki 41 a makonni huɗu bayan haɓakawa. An gano rigakafin BNT162b2 don haɓaka titers antibody zuwa matsayi mafi girma a cikin mako biyu bayan haɓakawa, kafin ƙin wakiltar haɓaka sau 17 a mako huɗu bayan haɓakawa. Haɓaka ci gaba a cikin ƙwayoyin rigakafi makonni bayan allurar rigakafi na Johnson & Johnson booster yayi kama da wanda aka gani biyo bayan rigakafin farko. Saurin amsawar rigakafin da ke biye da raguwar amsawar antibody bayan mai haɓaka BNT162b2 shima yayi kama da wanda aka gani biyo bayan tsarin farko na kashi biyu.

Alurar rigakafin Johnson & Johnson COVID-19 ya haɓaka median Omicron-reactive CD8+ T-cells da ninki 5.5, da Omicron-reactive CD4+ T-cells da ninki 3.1, yayin da tsarin homologue (BNT162b2) ya haɓaka duka Omicron-reactive CD4+ da CD8+ T-kwayoyin ta 1.4-ninka.

Kwayoyin T-suna iya kaiwa hari da lalata ƙwayoyin sel waɗanda kwayar cutar ta kamu da cutar da ke haifar da COVID-19 kuma an yi imanin suna ba da gudummawar kariya daga kamuwa da cuta mai tsanani. Musamman, CD8+ T-cell suna iya lalata ƙwayoyin cuta kai tsaye kuma CD4+ T-cell suna taimakon su.

Wadannan bayanan sun nuna cewa haɓakar haɓakar haɓakar haɓaka yana da yuwuwar haifar da haɓakar rigakafi mai ƙarfi ta tantanin halitta, wanda ke da mahimmanci ga ƙwaƙwalwar ƙwaƙwalwar ƙwaƙwalwa da kariya daga mummunan cututtukan ƙwayar cuta na numfashi. Za a iya tantance dorewar tsarin haɓakawa da haɓakar yanayin yanayin SARS-CoV-2 Omicron.

ƙarin Bayani

An ba da izinin rigakafin Johnson & Johnson COVID-19 a matsayin mai ƙarfafawa ta hanyar masu gudanarwa da yawa da hukumomin kiwon lafiya a duniya. Johnson & Johnson na ci gaba da gabatar da bayanan da suka dace ga sauran masu mulki, Hukumar Lafiya ta Duniya (WHO) da Kungiyoyin Ba da Shawarwari na Fasaha ta Kasa (NITAGs) a duk duniya don sanar da yanke shawara kan dabarun sarrafa rigakafin na gida, kamar yadda ake bukata.

A ranar 16 ga Disamba, 2021, Cibiyar Kula da Cututtuka da Cututtuka ta Amurka (CDC) ta amince da sabbin shawarwarin da Kwamitin Ba da Shawarwari kan Ayyukan Rigakafi (ACIP) ya bayar don rigakafin COVID-19, yana bayyana fifikon asibiti don daidaikun mutane don karɓar mRNA COVID -19 allurar rigakafin cutar COVID-19 na Johnson & Johnsons. A cikin Amurka, mutanen da ba su iya ko ba sa son karɓar maganin mRNA za su ci gaba da samun damar yin amfani da rigakafin Johnson & Johnson COVID-19.

Alurar rigakafin Johnson & Johnson COVID-19 muhimmin zaɓi ne ga mutanen da ba za su iya ko ba za su dawo don allurar rigakafi da yawa ko waɗanda ba za su kasance ba tare da madadin allurar mRNA ba. Alurar rigakafin COVID-19 ta Johnson & Johnson ta yi daidai da shawarwarin Hukumar Lafiya ta Duniya (WHO) don ba da agajin jinya a cikin wani yanayi na annoba, wanda ke jaddada sauƙin rarrabawa, gudanarwa, da bin doka.

Game da marubucin

Avatar na Linda Hohnholz

Linda Hohnholz

Edita a shugaba don eTurboNews bisa ga eTN HQ.

Labarai
Sanarwa na
bako
0 comments
Bayanin Cikin Lissafi
Duba duk maganganu
0
Za a son tunanin ku, don Allah sharhi.x
()
x
Share zuwa...